Works matching IS 00302414 AND DT 2023 AND VI 101
Results: 108
Front & Back Matter.
- Published in:
- Oncology, 2023, v. 101, n. 12, p. 764, doi. 10.1159/000535850
- Publication type:
- Article
Contents Vol. 101, 2023.
- Published in:
- Oncology, 2023, v. 101, n. 12, p. I, doi. 10.1159/000535209
- Publication type:
- Article
Erratum.
- Published in:
- 2023
- Publication type:
- Correction Notice
High-Mobility Group Box 1 Overexpression Predicts a Poor Prognosis and Promotes Epithelial-Mesenchymal Transition in Gastric Cancer by Activating TLR4/NF-κB Signaling.
- Published in:
- Oncology, 2023, v. 101, n. 12, p. 786, doi. 10.1159/000533927
- By:
- Publication type:
- Article
The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
- Published in:
- Oncology, 2023, v. 101, n. 12, p. 836, doi. 10.1159/000533866
- By:
- Publication type:
- Article
Adverse Metabolic Effects on Glucose in Patients Receiving Anamorelin Using a Japanese Claims Database.
- Published in:
- Oncology, 2023, v. 101, n. 12, p. 782, doi. 10.1159/000533539
- By:
- Publication type:
- Article
Significance of Ultra-Radical Surgery in Extensive Metastatic Ovarian Growing Teratoma Syndrome.
- Published in:
- Oncology, 2023, v. 101, n. 12, p. 773, doi. 10.1159/000533411
- By:
- Publication type:
- Article
Comparing COVID-19 Response Behaviors between a Cancer Patient Sample and a Population-Based Cancer-Free Sample in a Rural Midwestern State.
- Published in:
- Oncology, 2023, v. 101, n. 12, p. 808, doi. 10.1159/000533408
- By:
- Publication type:
- Article
Evaluation of Time to Onset and Outcome of Cardiac Adverse Events Associated with Nilotinib using Post-Marketing Surveillance.
- Published in:
- Oncology, 2023, v. 101, n. 12, p. 799, doi. 10.1159/000533325
- By:
- Publication type:
- Article
Evaluation of Time to Onset and Outcome of Lung Adverse Events Related to Pembrolizumab Using Marketing Surveillance.
- Published in:
- Oncology, 2023, v. 101, n. 12, p. 817, doi. 10.1159/000533302
- By:
- Publication type:
- Article
Retrospective Study of Treatment Patterns and Natural History of Patients with T1a/b N0 Triple-Negative Breast Cancers: A Single-Institution Experience.
- Published in:
- Oncology, 2023, v. 101, n. 12, p. 765, doi. 10.1159/000533149
- By:
- Publication type:
- Article
Efficacy of Autologous Hematopoietic Stem Cell Transplantation versus Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation for Follicular Lymphoma: Systematic Review and Meta-Analysis.
- Published in:
- Oncology, 2023, v. 101, n. 12, p. 822, doi. 10.1159/000532090
- By:
- Publication type:
- Article
Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 738, doi. 10.1159/000533303
- By:
- Publication type:
- Article
Front & Back Matter.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 1, doi. 10.1159/000534780
- Publication type:
- Article
Postoperative Early Body Weight Loss Is a Risk Factor for Recurrence in Patients with pStage III Gastric Cancer.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 705, doi. 10.1159/000532089
- By:
- Publication type:
- Article
The Glasgow Prognostic Score Predicts Survival Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 695, doi. 10.1159/000532087
- By:
- Publication type:
- Article
Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 730, doi. 10.1159/000531870
- By:
- Publication type:
- Article
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 723, doi. 10.1159/000531722
- By:
- Publication type:
- Article
Circulating Cell-Free DNA as a Biomarker for Prognosis and Response to Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 714, doi. 10.1159/000531671
- By:
- Publication type:
- Article
Lower Body Mass Index and Prognostic Nutritional Index Are Associated with Poor Posttransplant Outcomes in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 753, doi. 10.1159/000531576
- By:
- Publication type:
- Article
The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 685, doi. 10.1159/000530809
- By:
- Publication type:
- Article
Front & Back Matter.
- Published in:
- Oncology, 2023, v. 101, n. 10, p. 1, doi. 10.1159/000534426
- Publication type:
- Article
Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2023, v. 101, n. 10, p. 655, doi. 10.1159/000531689
- By:
- Publication type:
- Article
Effects of Lenvatinib on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma.
- Published in:
- Oncology, 2023, v. 101, n. 10, p. 634, doi. 10.1159/000531562
- By:
- Publication type:
- Article
Intralesional Chemotherapy for Prostate Cancer: In vivo Proof of Principle.
- Published in:
- Oncology, 2023, v. 101, n. 10, p. 645, doi. 10.1159/000531494
- By:
- Publication type:
- Article
Recent Developments in Diagnostic and Prognostic Biomarkers for Colorectal Cancer: A Narrative Review.
- Published in:
- Oncology, 2023, v. 101, n. 10, p. 675, doi. 10.1159/000531474
- By:
- Publication type:
- Article
Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.
- Published in:
- Oncology, 2023, v. 101, n. 10, p. 664, doi. 10.1159/000531390
- By:
- Publication type:
- Article
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
- Published in:
- Oncology, 2023, v. 101, n. 10, p. 624, doi. 10.1159/000531316
- By:
- Publication type:
- Article
Impact of Renal Function on the Prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2023, v. 101, n. 10, p. 609, doi. 10.1159/000531111
- By:
- Publication type:
- Article
Front & Back Matter.
- Published in:
- Oncology, 2023, v. 101, n. 9, p. 1, doi. 10.1159/000533949
- Publication type:
- Article
Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy.
- Published in:
- Oncology, 2023, v. 101, n. 9, p. 584, doi. 10.1159/000531318
- By:
- Publication type:
- Article
Response Prediction Model of Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Retrospective Study.
- Published in:
- Oncology, 2023, v. 101, n. 9, p. 565, doi. 10.1159/000531317
- By:
- Publication type:
- Article
Overexpression of SOX2 Gene by Histone Modifications: SOX2 Enhances Human Prostate and Breast Cancer Progression by Prevention of Apoptosis and Enhancing Cell Proliferation.
- Published in:
- Oncology, 2023, v. 101, n. 9, p. 591, doi. 10.1159/000531195
- By:
- Publication type:
- Article
Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria.
- Published in:
- Oncology, 2023, v. 101, n. 9, p. 575, doi. 10.1159/000530987
- By:
- Publication type:
- Article
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
- Published in:
- Oncology, 2023, v. 101, n. 9, p. 542, doi. 10.1159/000530028
- By:
- Publication type:
- Article
Efficacy of Lipophilic Statins on Outcomes of Patients Treated with Immune Checkpoint Inhibitors.
- Published in:
- Oncology, 2023, v. 101, n. 9, p. 537, doi. 10.1159/000529644
- By:
- Publication type:
- Article
Neoadjuvant Management of Adenocarcinoma of the Esophagus and Esophagogastric Junction: Review of Randomized Evidence and Definition of Optimum Treatment Algorithm.
- Published in:
- Oncology, 2023, v. 101, n. 9, p. 553, doi. 10.1159/000527716
- By:
- Publication type:
- Article
Front & Back Matter.
- Published in:
- Oncology, 2023, v. 101, n. 8, p. 1, doi. 10.1159/000533681
- Publication type:
- Article
Infiltration of Gastric Cancer Stroma by Tumor-Infiltrating Lymphocytes Correlates with Mechanistic Target of Rapamycin Signaling.
- Published in:
- Oncology, 2023, v. 101, n. 8, p. 520, doi. 10.1159/000531475
- By:
- Publication type:
- Article
Peripheral Blood-Derived CircVPS35L as a Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer.
- Published in:
- Oncology, 2023, v. 101, n. 8, p. 527, doi. 10.1159/000531357
- By:
- Publication type:
- Article
Circulating Tumor Cells as Diagnostic Markers of Early Gastric Cancer and Gastric Precancerous Lesions.
- Published in:
- Oncology, 2023, v. 101, n. 8, p. 512, doi. 10.1159/000531323
- By:
- Publication type:
- Article
Comparison of Paclitaxel plus Carboplatin versus Observation in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck.
- Published in:
- Oncology, 2023, v. 101, n. 8, p. 502, doi. 10.1159/000531026
- By:
- Publication type:
- Article
The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.
- Published in:
- Oncology, 2023, v. 101, n. 8, p. 491, doi. 10.1159/000530991
- By:
- Publication type:
- Article
Diagnostic Value of OPNI in Hepatocellular Carcinoma.
- Published in:
- Oncology, 2023, v. 101, n. 8, p. 481, doi. 10.1159/000530319
- By:
- Publication type:
- Article
The Utility of SUV<sub>max</sub> as an Adaptation Criterion for Limited Resection in Stage IA Non-Small Cell Lung Cancer.
- Published in:
- Oncology, 2023, v. 101, n. 8, p. 473, doi. 10.1159/000530314
- By:
- Publication type:
- Article
The Cancer Treatment Gap in Lower- to Middle-Income Countries.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Preface.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Practical Notes on the Current ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer in Resource-Constrained Environments of Low- to Middle-Income Countries.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Front & Back Matter.
- Published in:
- Oncology, 2023, v. 101, n. 7, p. 1, doi. 10.1159/000533557
- Publication type:
- Article
Predictive Factors Associated with Long-Term Response to Combination Immunotherapy in Patients with Untreated Advanced Non-Small-Cell Lung Cancer: A Multicenter Retrospective Study.
- Published in:
- Oncology, 2023, v. 101, n. 7, p. 425, doi. 10.1159/000531324
- By:
- Publication type:
- Article